Sarcoma
(Jan 1999)
Hyperthermic Isolated Limb Perfusion with TNF α
and Cisplatin in the
Treatment of Osteosarcoma of the Extremities: A Feasibility Study in
Healthy Dogs
Robert J. Van Ginkel,
Charles L. H. Van Berlo,
Peter C. Baas,
Heimen Schraffordt Koops,
Ries Van Groningen B. Stuling,
Jan Elstrodt,
Harald J. Hoekstra
Affiliations
Robert J. Van Ginkel
Department of Surgical Oncology, Division of Surgical Oncology, Groningen University Hospital, PO Box 30.001, Groningen 9700 RB, The Netherlands
Charles L. H. Van Berlo
Department of Surgical Oncology, Division of Surgical Oncology, Groningen University Hospital, PO Box 30.001, Groningen 9700 RB, The Netherlands
Peter C. Baas
Department of Surgical Oncology, Division of Surgical Oncology, Groningen University Hospital, PO Box 30.001, Groningen 9700 RB, The Netherlands
Heimen Schraffordt Koops
Department of Surgical Oncology, Division of Surgical Oncology, Groningen University Hospital, PO Box 30.001, Groningen 9700 RB, The Netherlands
Ries Van Groningen B. Stuling
Department of Surgical Oncology, Division of Surgical Oncology, Groningen University Hospital, PO Box 30.001, Groningen 9700 RB, The Netherlands
Jan Elstrodt
Central Animal Laboratory, Groningen University Hospital, Groningen, The Netherlands
Harald J. Hoekstra
Department of Surgical Oncology, Division of Surgical Oncology, Groningen University Hospital, PO Box 30.001, Groningen 9700 RB, The Netherlands
DOI
https://doi.org/10.1080/13577149977703
Journal volume & issue
Vol. 3,
no. 2
Abstract
Read online
Purpose. The feasibility of hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor-α (TNFα ) and cisplatin for the management of osteosarcoma was studied in the canine model.
WeChat QR code
Close
